An observational study in Skin Mycoses, sponsored by LEO Pharma. Completed at 1 site in Russian Federation. Per ClinicalTrials.gov, last updated 2023-06-09.
Sponsored by LEO Pharma · Observational
An assessment of the efficacy and safety of Travogen cream and Travocort cream in the treatment of local skin mycoses
539 studies on the registry are indexed under Mycoses; 55 are open to participants now.
This study's enrollment of 900 is above the median of 152 across 150 observational studies indexed under Mycoses.
Browse Mycoses studies →LEO Pharma is the lead sponsor of 221 studies on the registry; 5 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 24 (77%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with diagnosed skin mycoses
Exclusion Criteria:
All patients treated
Efficacy of Travogen / Travocort in the treatment of skin mycoses / Travogen Cream and Travocort Cream will be prescribed by a physician
Time frame: Baseline to end of study
Patient satisfaction
Time frame: Baseline to end of study
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
LEO Pharma